CAREER DEVELOPMENT AWARD IN PEDIATRIC PSYCHOPHARMACOLOGY

儿科精神药理学职业发展奖

• 批准号: 6625370
• 负责人: ANDRES S MARTIN
• 金额: $ 14.78万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2004-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6625370
• 关键词: Asperger syndrome; adolescence (12-20); antidepressants; antipsychotic agents; anxiety disorders; autism; clinical research; human subject; human therapy evaluation; impulsive behavior; mental disorder chemotherapy; middle childhood (6-11); pediatric pharmacology; piperazines; psychopharmacology; serotonin inhibitor; tranquilizer

The proposed Mentored Scientist Development Award for New Minority Faculty (K01-MSDA-NMF) outlines a program of career development in clinical, patient-centered research in pediatric psychopharmacology, and specifically focused on the pervasive developmental disorders (PDDs). Over the past two years, and while supported by a grant from the Program for Minority Research Training in Psychiatry (PMRTP), I have been productively engaged in this area of clinical research. I have participated in Yale s successful application for a Research Unit in Pediatric Psychopharmacology (RUPP) contract focused on the PDDs, been involved in the design and implementation of multi-site collaborative efforts, conducted smaller scale clinical trials, and completed naturalistic studies in psychopharmacology and in other developmental disabilities, such as Prader-Willi syndrome. The proposed K01 would provide me with an opportunity to acquire the necessary additional skills and training to become an independent researcher in pediatric psychopharmacology. To achieve my long-term goal of scientific independence, a comprehensive training plan has been designed to complement my proposed research activities. Under the primary mentorship of James F. Leckman, M.D., I have developed a curriculum of formal didactics, seminars, tutorials and extramural site visits that will focus on the key areas of: 1) Pharmacodynamic and pharmacokinetic principles; 2) PDD nosology and assessment; 3) Clinical trial methodology; 4) Ethical conduct of science; 5) Statistics and quantitative skills; 6) Basic aspects of health services and effectiveness research; and 7) Organizational, administrative, and grant-writing skills. Two studies that build on preliminary clinical trials in the field are proposed as the context and the practical substrate for the training plan described: 1) A double-blind, placebo- controlled study of low-dose fluvoxamine in the treatment of obsessive, compulsive, and general anxiety symptoms in adolescents diagnosed with Asperger s syndrome; and 2) A pilot, open-label study of ziprasidone, conducted under Investigational New Drug (IND) approval from the Food and Drug Administration (FDA), in the treatment of aggressive, impulsive and self- injurious behaviors associated with autistic disorder.

拟议的新少数民族教师（K01-MSDA-NMF）的指导科学家发展奖概述了一项在儿科心理学领域的临床，以患者为中心的研究方面的职业发展计划，并专门针对普遍的发育障碍（PDDS）。在过去的两年中，我得到了精神病学少数群体研究培训计划（PMRTP）的赠款的支持，但我一直在有效地参与了这一临床研究领域。我参加了耶鲁大学的成功申请，以研究和实施多站点协作工作的设计和实施，从事PDD的小儿心理药理学（RUPP）合同，进行了较小的规模临床试验，并完成了心理治疗学和其他发育障碍的自然主义研究，并在其他发展疾病中进行了自然主义研究。 拟议的K01将为我提供机会，以获取必要的其他技能和培训，以成为小儿心理药理学的独立研究人员。为了实现我的长期科学独立目标，已经设计了一项全面的培训计划，以补充我拟议的研究活动。 在医学博士James F. Leckman的主要指导下，我开发了正式的教学，研讨会，教程和壁外场地访问的课程，这些课程将重点放在：1）药物学和药物动力学原理的关键领域； 2）PDD典型和评估； 3）临床试验方法； 4）科学的道德行为； 5）统计和定量技能； 6）卫生服务和有效性研究的基本方面； 7）组织，行政和赠款技巧。提出了两项​​基于该领域初步临床试验的研究，作为描述的训练计划的背景和实际底物：1）在治疗急诊症诊断为Asperger S综合症的青少年中，低剂量氟氟众胺的双盲，安慰剂控制的研究；和2）一项针对食品药品监督管理局（FDA）的研究新药（IND）批准进行的Ziprasidone的试验性研究，以治疗与自动疾病相关的侵略性，冲动和自我伤害行为。